Exogenous estrogen in systemic lupus erythematosus: Oral contraceptives and hormone replacement therapy

Research output: Contribution to journalReview articlepeer-review

Abstract

The role of exogenous estrogen in the initiation and maintenance of human SLE remains very controversial. Although cohort studies suggest an increase in the incidence of SLE with both oral contraceptives and hormone replacement therapy, recent retrospective studies suggest that the risk of flare is not increased with hormone replacement therapy. However, exogenous estrogen does increase hypercoagulability, an issue in SLE patients with antiphospholipid antibodies. The prospective SELENA study will ultimately address whether exogenous estrogen increases severe flares in SLE.

Original languageEnglish (US)
Pages (from-to)222-226
Number of pages5
JournalLupus
Volume10
Issue number3
DOIs
StatePublished - May 17 2001

Keywords

  • Hormone replacement therapy
  • Oral contraceptives
  • SLE

ASJC Scopus subject areas

  • Rheumatology

Fingerprint Dive into the research topics of 'Exogenous estrogen in systemic lupus erythematosus: Oral contraceptives and hormone replacement therapy'. Together they form a unique fingerprint.

Cite this